Section Arrow
VERV.NASDAQ
- Verve Therapeutics
Quotes are at least 15-min delayed:2025/07/16 09:17 EDT
Regular Hours
Last
 --
-- (--)
Day High 
-- 
Prev. Close
11.02 
1-M High
11.405 
Volume 
-- 
Bid
11.04
Ask
11.05
Day Low
-- 
Open
-- 
1-M Low
5.9421 
Market Cap 
984.22M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 11.13 
20-SMA 10.92 
50-SMA 7.31 
52-W High 11.405 
52-W Low 2.8647 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.11/-2.76
Enterprise Value
1.04B
Balance Sheet
Book Value Per Share
5.30
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
32.33M
Operating Revenue Per Share
0.09
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks----0.000%-- 
ZVSAZyVersa Therapeutics----0.000%0PE
ZVRAZevra Therapeutics----0.000%-- 
ZURAZura Bio Limited----0.000%5.54PE
ZNTLZentalis Pharmaceuticals----0.000%-- 
Quotes are at least 15-min delayed:2025/07/16 09:17 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.